These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38242283)

  • 21. CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity.
    Jie J; Zhang Y; Zhou H; Zhai X; Zhang N; Yuan H; Ni W; Tai G
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29558459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
    Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
    ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses.
    Madan-Lala R; Pradhan P; Roy K
    Sci Rep; 2017 May; 7(1):2530. PubMed ID: 28566683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
    Volckmar J; Knop L; Stegemann-Koniszewski S; Schulze K; Ebensen T; Guzmán CA; Bruder D
    Vaccine; 2019 Aug; 37(35):4963-4974. PubMed ID: 31320219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA.
    Wagner M; Poeck H; Jahrsdoerfer B; Rothenfusser S; Prell D; Bohle B; Tuma E; Giese T; Ellwart JW; Endres S; Hartmann G
    J Immunol; 2004 Jan; 172(2):954-63. PubMed ID: 14707068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.
    Wille-Reece U; Wu CY; Flynn BJ; Kedl RM; Seder RA
    J Immunol; 2005 Jun; 174(12):7676-83. PubMed ID: 15944268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do.
    Najar HM; Dutz JP
    Eur J Immunol; 2007 Aug; 37(8):2242-56. PubMed ID: 17634951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
    Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
    J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant.
    Andreakos E; Williams RO; Wales J; Foxwell BM; Feldmann M
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14459-64. PubMed ID: 16971487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The adjuvant BcfA activates antigen presenting cells through TLR4 and supports T
    Shamseldin MM; Read KA; Hall JM; Tuazon JA; Brown JM; Guo M; Gupta YA; Deora R; Oestreich KJ; Dubey P
    Front Immunol; 2024; 15():1439418. PubMed ID: 39267766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Species-dependent role of type I IFNs and IL-12 in the CTL response induced by humanized CpG complexed with β-glucan.
    Kobiyama K; Temizoz B; Kanuma T; Ozasa K; Momota M; Yamamoto T; Aoshi T; Kuroda E; Ishii KJ
    Eur J Immunol; 2016 May; 46(5):1142-51. PubMed ID: 26786557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.
    Scheiermann J; Klinman DM
    Vaccine; 2014 Nov; 32(48):6377-89. PubMed ID: 24975812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates.
    Wille-Reece U; Flynn BJ; Loré K; Koup RA; Miles AP; Saul A; Kedl RM; Mattapallil JJ; Weiss WR; Roederer M; Seder RA
    J Exp Med; 2006 May; 203(5):1249-58. PubMed ID: 16636134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells.
    Taylor PR; Koski GK; Paustian CC; Bailey E; Cohen PA; Moore FB; Zimmerman DH; Rosenthal KS
    Vaccine; 2010 Aug; 28(34):5533-42. PubMed ID: 20600501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Nontoxic Cholera B Subunit Is a Potent Adjuvant for Intradermal DC-Targeted Vaccination.
    Antonio-Herrera L; Badillo-Godinez O; Medina-Contreras O; Tepale-Segura A; García-Lozano A; Gutierrez-Xicotencatl L; Soldevila G; Esquivel-Guadarrama FR; Idoyaga J; Bonifaz LC
    Front Immunol; 2018; 9():2212. PubMed ID: 30319653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity.
    Dasari V; Smith C; Schuessler A; Zhong J; Khanna R
    Hum Vaccin Immunother; 2014; 10(4):1064-77. PubMed ID: 24463331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel adjuvant CoVaccineHT increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro.
    Bodewes R; Geelhoed-Mieras MM; Heldens JG; Glover J; Lambrecht BN; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    Vaccine; 2009 Nov; 27(49):6833-9. PubMed ID: 19772942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of different combination of pam2CSK4, poly (I:C) and imiquimod enhance immune responses to H9N2 avian influenza antigen in dendritic cells and duck.
    Zhang A; Li D; Song C; Jing H; Li H; Mi J; Zhang G; Jin S; Ren X; Huangfu H; Shi D; Chen R
    PLoS One; 2022; 17(7):e0271746. PubMed ID: 35853030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.